A Badros

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. pmc Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
    A Z Badros
    M and S Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
    Leukemia 27:1707-14. 2013
  2. ncbi request reprint ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Transfusion 42:205-9. 2002
  3. ncbi request reprint Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Ashraf Z Badros
    Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 23:4089-99. 2005
  4. ncbi request reprint Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
    Ashraf Badros
    University of Maryland and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Clin Oncol 24:945-52. 2006
  5. ncbi request reprint Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 20:1295-303. 2002
  6. ncbi request reprint Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:822-9. 2001
  7. ncbi request reprint Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
    Ashraf Badros
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Cancer 110:1042-9. 2007
  8. ncbi request reprint Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma
    Ashraf Badros
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    Clin Lymphoma Myeloma 7:210-6. 2006
  9. doi request reprint Natural history of osteonecrosis of the jaw in patients with multiple myeloma
    Ashraf Badros
    University of Maryland, Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 26:5904-9. 2008
  10. pmc Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma
    Ashraf Badros
    University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Clin Cancer Res 15:5250-7. 2009

Detail Information

Publications44

  1. pmc Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
    A Z Badros
    M and S Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
    Leukemia 27:1707-14. 2013
    ..In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy...
  2. ncbi request reprint ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Transfusion 42:205-9. 2002
    ..Blood group incompatibility does not appear to affect the overall outcome in patients undergoing myeloablative conditioning before allogeneic BMT. Data on ABO-mismatched transplantation in the nonmyeloablative setting are limited...
  3. ncbi request reprint Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Ashraf Z Badros
    Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 23:4089-99. 2005
    ..Bcl-2 regulates the mitochondrial apoptosis pathway that promotes chemotherapy resistance. Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA...
  4. ncbi request reprint Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
    Ashraf Badros
    University of Maryland and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Clin Oncol 24:945-52. 2006
    ..To describe the clinical, radiologic, and pathologic features and risk factors for osteonecrosis of the jaw (ONJ) in multiple myeloma (MM) patients...
  5. ncbi request reprint Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 20:1295-303. 2002
    ..We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft)...
  6. ncbi request reprint Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:822-9. 2001
    ..MEL-140 had an acceptable toxicity and appeared equally effective as MEL-200. In the setting of renal failure, the role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation...
  7. ncbi request reprint Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
    Ashraf Badros
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Cancer 110:1042-9. 2007
    ..Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)...
  8. ncbi request reprint Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma
    Ashraf Badros
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    Clin Lymphoma Myeloma 7:210-6. 2006
    ..In preclinical studies, bortezomib was shown to suppress tumor growth, sensitize malignant cells to apoptosis, and reverse chemotherapy resistance...
  9. doi request reprint Natural history of osteonecrosis of the jaw in patients with multiple myeloma
    Ashraf Badros
    University of Maryland, Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 26:5904-9. 2008
    ..To evaluate the natural history of bisphosphonate-related osteonecrosis of the jaw (ONJ) in patients with multiple myeloma...
  10. pmc Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma
    Ashraf Badros
    University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Clin Cancer Res 15:5250-7. 2009
    ..Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro. We sought to test the combination clinically...
  11. ncbi request reprint Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait
    Ashraf Badros
    University of Maryland, Greenebaum Cancer Center, Baltimore, MD, 21201, USA
    Clin Adv Hematol Oncol 3:916-7; discussion 918. 2005
  12. ncbi request reprint Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, USA
    Leuk Lymphoma 43:1267-71. 2002
    ..The use of thalidomide should be carefully assessed in relapsed multiple myeloma patients with clinical and cytogenetic evidence of t-MDS...
  13. ncbi request reprint Transplantation as salvage therapy for high-risk patients with myeloma in relapse
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 30:873-8. 2002
    ..001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors...
  14. ncbi request reprint Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:600-7. 2001
    ..In conclusion, MEL-140 is less toxic and appears equally as efficacious as MEL-200 in elderly patients. The benefits of tandem SCT in this patient population need further evaluation in a randomized trial...
  15. ncbi request reprint Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    M Zangari
    Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 98:1614-5. 2001
    ....
  16. ncbi request reprint Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma
    A P Rapoport
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Bone Marrow Transplant 34:883-90. 2004
    ..5 years, EFS=87%). There were no treatment-related deaths during or after the CC phase. Post-transplant CC is feasible and well tolerated. The impact of this approach on EFS should be evaluated in a larger, randomized study...
  17. ncbi request reprint Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Bone Marrow Transplant 37:511-5. 2006
    ....
  18. ncbi request reprint Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
    K R Desikan
    The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 112:242-7. 2001
    ..e. beta(2)-microglobulin levels > 2.5 mg/l, probably benefit from chemotherapy for mobilization both in terms of cytoreduction and adequate stem cell mobilization resulting in accelerated engraftment...
  19. ncbi request reprint Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
    M Zangari
    Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Blood Coagul Fibrinolysis 13:187-92. 2002
    ..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT...
  20. ncbi request reprint Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 98:492-4. 2001
    ..Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM...
  21. ncbi request reprint High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    A Badros
    Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
    Blood 97:2574-9. 2001
    ..Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure...
  22. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
    ..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)...
  23. ncbi request reprint Clinical activity of arsenic trioxide for the treatment of multiple myeloma
    N C Munshi
    University of Arkansas for Medical Sciences, Myeloma and Transplantation Medical Center, Little Rock, AR, USA
    Leukemia 16:1835-7. 2002
    ..The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM...
  24. ncbi request reprint Thalidomide in the management of multiple myeloma
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Semin Hematol 38:250-9. 2001
    ..The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy. Newer, more potent, and less toxic derivatives of thalidomide are being evaluated...
  25. ncbi request reprint Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
    Athanasios B T Fassas
    Myeloma and Transplantation Research Center, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 117:103-8. 2002
    ..Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting...
  26. ncbi request reprint Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells
    A P Rapoport
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Bone Marrow Transplant 33:53-60. 2004
    ..Autotransplantation followed by costimulated autologous T cells is feasible for patients with chronic phase CML, who lack allogeneic donors and can be associated with molecular remissions...
  27. ncbi request reprint Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma
    S H Lim
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cancer 91:900-8. 2001
    ..The authors reasoned that if there is any specific T-cell/tumor cell interaction in myeloma, it is most likely reflected in the T-cell population in the vicinity of the tumor cells...
  28. ncbi request reprint Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
    A P Rapoport
    Greenebaum Cancer Center and Stem Cell Transplantation Program, University of Maryland School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 29:303-12. 2002
    ..015). In conclusion, post-transplant consolidation therapy is feasible and well-tolerated for patients autografted for aggressive NHL and HD and may be associated with improved progression-free survival particularly for patients with HD...
  29. ncbi request reprint Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
    Aaron P Rapoport
    University of Maryland Greenebaum Cancer Center and Center for Vaccine Development, 22 South Greene Street Baltimore, Maryland 21201, USA
    Nat Med 11:1230-7. 2005
    ..05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses...
  30. ncbi request reprint Tandem transplantation in multiple myeloma
    Javier BolaƱos-Meade
    Bone Marrow Transplant Program, University of Maryland, Greenebaum Cancer Center, Blood and Marrow Transplant Program, Baltimore, Maryland, USA
    Oncology (Williston Park) 17:389-98; discussion 398-400, 405-7. 2003
    ..Until the efficacy and safety of this procedure is fully established, it should be limited to high-risk patients...
  31. ncbi request reprint Separating graft-versus-tumor from graft-versus-host reactions
    A B T Fassas
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Leuk Lymphoma 43:725-33. 2002
    ....
  32. ncbi request reprint Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
    Guido Tricot
    The Myeloma and Transplantation Research Center and the Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 116:211-7. 2002
    ..or = 7 years and re-establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression > or = 7 years...
  33. ncbi request reprint Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients
    Naoko Takebe
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Clin Cancer Res 10:8301-8. 2004
    ..On the basis of our preclinical studies, we designed a clinical study to test our hypothesis that MMF has antimyeloma activity...
  34. pmc Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis
    Mark A Scheper
    Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland Medical Center, Baltimore, MD 21201, USA
    Br J Haematol 144:667-76. 2009
    ..These findings support the potential for soft tissue injury as an initiating/potentiating event for osteonecrosis...
  35. ncbi request reprint Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors
    April Deng
    Department of Dermatology, University of Maryland, Baltimore 21201, USA
    Arch Dermatol 142:198-202. 2006
    ..Although anti-TNF-alpha therapy is safe and well tolerated, various adverse cutaneous reactions have been reported...
  36. ncbi request reprint Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation
    Benjamin Bridges
    University of Maryland, Baltimore, 21201, USA
    Am J Hematol 81:535-7. 2006
    ..Our case suggests that local cidofovir therapy for viral hemorrhagic cystitis is effective and well tolerated with no observed side effects...
  37. doi request reprint A novel bioassay model to determine clinically significant bisphosphonate levels
    Mark A Scheper
    Department of Diagnostic Sciences and Pathology, University of Maryland Medical Center, 650 W Baltimore Street, 7 N, Baltimore, MD 21201, USA
    Support Care Cancer 17:1553-7. 2009
    ..The objective of this current study was to develop a novel bioassay model representative of the oral levels of BPs in patients presenting with or at risk for BON...
  38. ncbi request reprint Scleritis complicating zoledronic acid infusion
    David Benderson
    Department of Ophthalmology, University of Maryland, Baltimore, MD 21201, USA
    Clin Lymphoma Myeloma 7:145-7. 2006
    ..Physicians prescribing these drugs should be aware of this side effect, which, if not recognized and treated appropriately, is potentially devastating. We review the published data as well as the current treatment recommendations...
  39. ncbi request reprint Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literature
    Karl M Kasamon
    Department of Hematology, Greenebaum Cancer Center, University of Maryland, Baltimore 21201, USA
    Haematologica 90:ECR17. 2005
    ..The case is discussed in the framework of the existing literature and derives clinical practice recommendations for this rare but clinically devastating entity...
  40. ncbi request reprint Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
    John Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:3849-56. 2003
    ....
  41. ncbi request reprint Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
    Ashraf Z Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Am J Med 112:412-3. 2002
  42. ncbi request reprint Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma
    Richard J Breyer
    Department of Radiology, University of Maryland Medical Center, 22 South Greene St, Baltimore, MD 21201, USA
    Skeletal Radiol 35:632-40. 2006
    ..To determine the usefulness of FDG PET/CT scanning in the management and staging of myeloma and to assess its strengths and limitations...
  43. ncbi request reprint Case 38-2004: a large tumor of the skull
    Ashraf Z Badros
    N Engl J Med 352:1610; author reply 1610. 2005
  44. ncbi request reprint Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites
    Yoshio Inoue
    University of Maryland, School of Medicine, Department of Medicine, 22 South Greene Street Baltimore, MD 21201, USA
    Leuk Res 29:715-8. 2005
    ..Involvement of serous cavities in myeloma carries a poor prognosis, and there is currently no standard effective treatment regimen...